Adults: The usual initial antihypertensive oral dose of NORVASC is 5 mg once
daily with a maximum dose of 10 mg once daily. Small, fragile, or elderly individuals,
or patients with hepatic insufficiency may be started on 2.5 mg once daily and this
dose may be used when adding NORVASC to other antihypertensive therapy.
Dosage should be adjusted according to each patient's need. In general, titration
should proceed over 7 to 14 days so that the physician can fully assess the patient's
response to each dose level. Titration may proceed more rapidly, however, if clinically
warranted, provided the patient is assessed frequently.
The recommended dose for chronic stable or vasospastic angina is 5–10 mg, with the
lower dose suggested in the elderly and in patients with hepatic insufficiency.
Most patients will require 10 mg for adequate effect. See ADVERSE REACTIONS section
for information related to dosage and side effects.
The recommended dose range for patients with coronary artery disease is 5–10 mg
once daily. In clinical studies the majority of patients required 10 mg (see CLINICAL
PHARMACOLOGY, Clinical Studies).
Children: The effective antihypertensive oral dose in pediatric patients
ages 6–17 years is 2.5 mg to 5 mg once daily. Doses in excess of 5 mg daily have
not been studied in pediatric patients. See CLINICAL PHARMACOLOGY.
Co-administration with Other Antihypertensive and/or Antianginal Drugs: NORVASC
has been safely administered with thiazides, ACE inhibitors, beta-blockers, long-acting
nitrates, and/or sublingual nitroglycerin.